Aug 16, 2017

IN-SITE #8 (Latvia): ”Att bryta mönster”

IN-SITE #8 handlar om Igor Lokots besök till Latvia under sin sommarresa till östra delen av Europa och betonar varför det är viktigt att bryta mönster […]
Aug 9, 2017

IN-SITE #7: Kiev

Double Bond Pharma IN-SITE #7 utspelar sig i Kiev, huvudstaden av Ukraina, där företagets VD Igor Lokot möter blivande samarbetspartners.
Aug 9, 2017

DOUBLE BOND actual #2: Björn Wallin om aktiehandel i små och stora bolag

I denna korta vlogg (video blogg) svarar Igor Lokot, VD för Double Bond, med hjälp av olika experter inom respektive branch på frekvent ställda frågor om […]
Aug 9, 2017

IN-SITE #6: ”Leverera styrkan där den behövs”

Follow Igor Lokot, CEO for Double Bond Pharmaceutical, on his summer vacation journey to Belarus. In-site #6: ”Bring power where it’s needed.”
Aug 4, 2017

IN-SITE #5: ”Lagspel”

Summer IN-SITE with CEO for Double Bond Pharma: episode #5, ”Lagspel”.
Aug 4, 2017

IN-SITE #4: ”Den lilla svampboken”

Follow CEO Igor Lokot on his summer trip to Belarus: IN-SITE#4, ”Den lilla svampboken”.
Aug 2, 2017


”Tanka mera och gasa på.”  
Jul 31, 2017

DOUBLE BOND actual #1: AstraZeneca Q&A

What happened to Astra Zeneca stock price last week and why – watch episode 1 of our new video series DOUBLE BOND actual.
Jul 29, 2017

In-site #2: Meetings in Minsk

Follow our CEO on his summer business trip to Belarus. In-site #2 takes place in Minsk.
Jul 28, 2017

Summer vacation with CEO Igor Lokot, part 1

Follow our CEO Igor Lokot on his summer trip to Belarus. Meetings, insights, thoughts and industry reflections.
Jul 4, 2017

Predictive biomarkers show the way

One of the important factors in drug development process is biomarker co-development. It is usually considered that efficacy-predicting biomarkers can potentially secure a...
Jun 14, 2017

Vinnare av DBP Challenge

Idag är vi glada att presentera vinnarna i tävlingen Double Bond Pharma Challenge! Tävlingen har pågått i över en månad och hade för avsikt att...
Apr 10, 2017

DBP Challenge – välj produkt och vinn 10 000 SEK

Om DBP Challenge Double Bond Pharmaceutical (DBP) är ett litet svensk läkemedelsbolag etablerat i oktober 2014 som jobbar för fullt med utveckling av säkrare behandlingar mot […]
Apr 7, 2017

Liver cancer treatment – what is next?

The modern drug design approach for anti-cancer products seems to be based on a concept that a disease can be cured if...
Apr 4, 2017

The F.A.Q. of the week

I have received quite a message from an investor that I would like to share with you. It was one of several similar questions...
Mar 29, 2017

Igor explains DBPs business model in a new video

A simple and humorous way to tell how we are different and why things we do are good...
Mar 21, 2017

Buy more popcorn – the story has only begun

What if there is no any well-defined boarders of the tumor? Just like in the case with brain cancers, for instance. There are honestly speaking “fifty shades of grey” here, and to be on the safe side the surgeon has to remove not only the...
Jan 10, 2017

Kvalitetssamordnare för GMP läkemedelsproduktion sökes till Double Bond Pharmaceutical AB

Vi söker en GMP manager med kunskaper inom kemi och QA erfarenhet inom läkemedel. Uppdraget innebär att ansvara för och koordinera produktionen av våra läkemedelskandidater. I arbetsuppgifterna ingår:
Dec 13, 2016

Live rich, drink coffee, smoke hash and stay home – unless you believe in SA-033

Live in a developed country, drink more coffee, smoke hash and stay at home waiting for clinical trial results with SA-033?! That's what the...
Dec 1, 2016

What if…?

Therapeutic window is a very crucial issue in drug development. It is a well-defined range of serum concentration of the drug at which the desired effect occurs, and below which there is little or no...
Nov 28, 2016

Hopes and hypes in cancer treatments. Part VI

We have tried to analyze the situation with ”hype trends” in drug development in several previous articles in order to understand (predict) what will be the next Big Thing. One very relevant question is...
Nov 8, 2016

Primary and secondary liver cancer

A very true and dramatic story, almost a detective narration with … Steve Jobs as a guest star
Nov 1, 2016

Hopes and hypes in cancer treatments. Part V

In the majority of cancer cases, the disease (presence of tumor) is detected at the late stage, when the treatment options are limited. Liver and brain cancers, for example, are those that often develop with...
Oct 28, 2016

Double Bond makes new trends

Double Bond is one of thousands of life-science companies, and in order to succeed we strive to be different, competitive and build our own unique path. Everything counts on the journey to...
Oct 25, 2016

Hopes and hypes in cancer treatments. Part IV

I have proposed in the previous part (Hypes and hopes in cancer treatments. Part III) that autotransplantation - the transplantation of organs, tissues, or even particular proteins from one part of the body to another...
Oct 20, 2016

Checker vs poker

DBP is, as many of you know, in a process of finding a partner for co-development of our front-line products: Temodex and SA-033. The partnering itself is very important...
Oct 17, 2016

Hopes and hypes in cancer treatments. Part III

If there are problems in the body – e.g. with different organs and tissues - let’s just change these organs. This paradigm becomes more and more popular these days and numerous efforts have been made to...
Oct 13, 2016

Liver Cancer: who to blame?

October is a liver cancer awareness month so let’s figure out what we could possibly do for fighting/prevention of liver cancer. Liver cancer is today the only cancer with a growing mortality. According to the diagram we can see that...
Oct 10, 2016

Hopes and hypes in cancer treatments. Part II

Play God With immunotherapy leaving the Peak of Inflated Expectations (see Part I), the question arises: what will be next? “Gene editing” is definitively one of […]
Oct 6, 2016

Drug delivery success stories

History of drug delivery originates from mid 19th century with an invention of a syringe. This invention is an example of a so called “disruptive innovation”, because...